Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

Journal of Clinical Medicine
Matthias UnseldGerald W Prager

Abstract

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects are rare. In this retrospective, observational, real-life study, clinical data on mCRC patients treated with trifluridine/tipiracil or regorafenib at the Medical University of Vienna, Austria and the University Hospital Zurich, Switzerland were collected. The correlation between adverse events and response or survival rates were calculated performing Fisher's exact test and log-rank test, respectively. Common adverse events of any grade included fatigue (52%), nausea/vertigo (34%), anemia (26%), and leukopenia (22%) in trifluridine/tipiracil patients and fatigue (42%), hand-foot-skin syndrome (36%) and hoarseness (34%) in patients upon regorafenib treatment. In trifluridine/tipiracil patients the prevalence of leukopenia (p = 0.044) and weight loss (p = 0.044) was prognostic, whereas leukopenia (p = 0.044) and neutropenia (p = 0.043) predicted PFS. The disease control rate was not significantly affected. In regorafenib-treated patien...Continue Reading

References

Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Oct 23, 2014·The New England Journal of Medicine·Fotios LoupakisAlfredo Falcone
May 15, 2015·The New England Journal of Medicine·Robert J MayerUNKNOWN RECOURSE Study Group
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Aug 16, 2016·Clinical Colorectal Cancer·Satoshi HamauchiHiroya Taniguchi
Mar 6, 2017·Oncology Reports·Nao KakizawaToshiki Rikiyama
Mar 30, 2017·Cancer Treatment Reviews·Andrés PovedaUNKNOWN GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research)
Nov 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YoshinoJ-Y Douillard

❮ Previous
Next ❯

Software Mentioned

SPSS Statistics
CONCUR

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.